Fulgent Genetics (FLGT) Financials

Fulgent Genetics’ latest quarter shows a company with a very strong balance sheet, but also one that is still struggling to convert revenue into profits. In Q1 2026, FLGT generated $71.1 million in revenue and produced $7.1 million in operating cash flow, yet it still posted a net loss of $24.8 million. The bigger picture is that the business now holds substantial cash and investments, which gives it flexibility, but earnings trends remain weak compared with prior years.

What stands out most: FLGT’s liquidity is excellent. As of March 31, 2026, the company had $23.4 million in cash, $252.9 million in short-term investments, and $328.3 million in long-term investments, compared with only $112.2 million in total liabilities. That leaves the company with a large net cash position and plenty of cushion to absorb losses or invest in growth.

• Strong balance sheet with $604.6 million in cash and investments combined, versus just $112.2 million in total liabilities.
• Operating cash flow was positive at $7.1 million in Q1 2026, showing the core business is still generating cash despite accounting losses.
• Gross profit remained healthy at $21.5 million on $71.1 million of revenue, implying the business still has meaningful margin on sales.
• Interest and investment income of $8.7 million helped offset operating losses.
• Total liabilities are low relative to equity and liquid assets, which reduces near-term financial risk.
• Revenue in Q1 2026 was down from $83.3 million in Q4 2025 and roughly flat to slightly lower than recent 2025 quarters, suggesting growth is not yet accelerating.
• The company completed a $55.6 million acquisition in Q1 2026, which could help future growth but also adds execution risk.
• FLGT repurchased $40.1 million of common equity in Q1 2026, which may support EPS over time but also uses cash that could otherwise be invested.
• The company reported an operating loss of $34.6 million in Q1 2026, indicating expenses are still well above gross profit.
• Net income attributable to common shareholders was a loss of $24.8 million in Q1 2026, so profitability remains elusive.

Looking at the trend over the last several years, revenue has been volatile and generally lower than the peak levels seen in 2022. Quarterly revenue was above $100 million in Q3 2022, but has mostly settled into the $70 million to $85 million range since then. That suggests FLGT is no longer operating at the very strong pandemic-era levels, and the business appears to be in a more mature, lower-growth phase.

Profitability has also weakened materially from the earlier period. FLGT was profitable in some quarters in 2022, but by 2024 and 2025 it was consistently posting losses. Q1 2026 was no exception. Operating expenses remain too high relative to gross profit, which means the company is still reliant on investment income and balance-sheet strength rather than operating earnings.

Cash generation is a brighter spot. Over the past several quarters, operating cash flow has swung around, but FLGT has generally remained able to produce cash from operations in many periods, even when net income was negative. That is a meaningful positive for investors because it helps explain why the company can continue funding itself without stressing the balance sheet.

Bottom line: FLGT looks financially resilient, but not fundamentally profitable yet. Investors are getting a company with a strong net cash position, positive operating cash flow in the latest quarter, and some strategic flexibility. On the other hand, revenue growth is uneven and losses remain substantial. The stock will likely depend on whether management can improve operating leverage and make recent investments and acquisitions translate into higher-quality earnings.